Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

A talk with the author of new research suggesting that an ADC may offer practice-changing, patient-friendly treatment of ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan ...

Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera.

Preliminary safety and efficacy results in 41 patients with pre-treated, advanced epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC) from the dose ...

Introduction. Since the early reference to plasmacytoid dendritic cells (pDCs) in the paracortical area of reactive lymph nodes in 1958 by Lennert and Remmele, [] an abundance of new information ...

Background: BPDCN is a rare, clinically aggressive hematological malignancy primarily involving the skin, bone marrow, and lymph nodes. CD123 (IL-3Rα) is highly overexpressed on the surface of all ...

Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.

Plasmacytoid dendritic cells (pDC) are the major IFN-I-producing cells, but this production returns to baseline soon after viral infection. Here the authors show that this decrease in IFN-I ...

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI ...